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Background
In the developing world many people are co-infected with
HIV and tuberculosis (TB). Recommended first-line
antiretroviral therapy (ART) commonly includes efavirenz
(EFV). Anti-tuberculous therapy includes rifampicin
(RFN). There remains debate about whether a dose
increase of EFV from the standard dose of 600 mg to an
increased dose of 800 mg daily is required with concomi-
tant RFN, which induces cytochrome p450 isoenzymes
that may reduce levels of EFV.
Methods
Individuals from the CIPRA-South Africa adult treatment
cohort on EFV-based ART with concomitant TB were
dosed with either an increased (800 mg) or standard (600
mg) dose of EFV during TB treatment. After TB therapy all
were given standard EFV doses. Two mid-dose EFV con-
centrations were determined from each individual: the
first after 4 weeks of concomitant EFV and RFN therapy,
and the second at least 4 weeks after TB therapy was com-
pleted. Mid-dose EFV concentrations were compared
across groups using the Mann-Whitney U-test and within
individuals using the Wilcoxon signed rank test.
Summary of results
Paired samples were collected from 60 individuals; 38
(63%) were women. The median weight was 60 kg (IQR
52–65 kg). The median CD4 count at ART baseline was
110 cells/mm3 (IQR 35–158), and median viral load 5.5
log (IQR 5.1–5.9). Thirty-one (52%) were taking 800 mg
EFV during TB treatment and 29 (48%) had the standard
dose. There was no significant difference in the median
EFV concentrations on RFN in the 800 mg group [3.2 ug/
ml (IQR 1.5–6.5)], compared to the 600 mg group [2.85
ug/ml (IQR 1.8–5.0)]. The median EFV concentrations off
RFN did not differ significantly either [800 mg group: 2.15
ug/ml (IQR 1.38–3.09); 600 mg group: 2.4 ug/ml (IQR
1.4 to 4.3)]. There was no evidence of a difference
between concentrations within the individual if on 600
mg dose at both timepoints nor if on 800 mg dose at first
time-point. There was no increase in EFV-linked adverse
effects in any group.
Conclusion
In our population there is no reduction in mid-dose EFV
concentrations with concomitant RFN therapy. The phar-
macogenetic profile cytochrome p450 isoenzyme, partic-
ularly the 2B6 isoenzyme, in this South African
population may differ from the other populations where
the majority of pharmacokinetic work has been com-
pleted. It was not necessary to increase the dose of EFV
during concomitant TB therapy in this South African pop-
ulation.
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